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Type 1 diabetes has been the leading form of 
diabetes among children and adolescents. As a
result of sedentary lifestyle and high-fat, high-
carbohydrate dietary habits, the prevalence and
the secular trends of incidence of type 2 diabetes
in early adolescence have increased in the past two
decades, including in Taiwan.1,2 Besides, the inci-
dence for type 1 diabetes has been shown to be
steady over these years.3 Therefore, correct differ-
ential diagnosis of pediatric diabetes is impor-
tant for the management plan.
In Caucasians, it has long been reported that
type 1 diabetes mellitus is an autoimmune disease
associated with the destruction of pancreatic β
cells.4 Several autoantibodies against pancreatic
β-cell autoantigens, including insulin, 65-kDa
glutamic acid decarboxylase (GAD65) and insuli-
noma antigen 2 (IA-2), a tyrosine-phosphatase-
like protein, have been detected in patients with
type 1 diabetes and their siblings.5–7 The presence
of β-cell autoantibodies in serum is used as a
marker for autoimmunity, and is specific for the
diagnosis of type 1 diabetes in children.8
Studies in Caucasians have shown that about
90% of patients with type 1 diabetes have at least
one of these β-cell autoantibodies detected.8–10
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The prevalence of type 1 diabetes is lower in Asians
than in Caucasians, and the difference in the fre-
quency of susceptible and protective genes can
explain partially such an ethnic difference.11,12
The positive rates of β-cell autoantibodies in pa-
tients with recent-onset type 1 diabetes in Japan
and Korea are reported to be similar to those in
Caucasians.13,14 However, the positive rate in
Chinese patients has been reported as lower than
that in Caucasians.15–19 In the present study, we
aimed to elucidate the prevalence of β-cell auto-
antibodies in newly diagnosed type 1 diabetes in
Taiwanese children, and its diagnostic value.
Moreover, we evaluated the correlation between
the presence of these β-cell autoantibodies and
residual β-cell function.
Patients and Methods
Patients
From 1989 to 2006, we enrolled 157 consecutive
Taiwanese patients, aged < 18 years, with newly
diagnosed type 1 diabetes, who were followed-up
at the Pediatric Endocrine Clinic of the National
Taiwan University Hospital. All of the patients
were evaluated within 3 weeks of diagnosis, which
was based on the report of the Expert Committee
held in 1997.20 All of the patients currently are
receiving insulin therapy.
Protocol
This study was approved by the Ethics Committee
of National Taiwan University Hospital. Informed
consent was obtained from the patients or their
parents. Metabolic status was evaluated by plasma
glycated hemoglobin levels, and metabolic decom-
pensation was assessed by the presence of ketoaci-
dosis, which was defined as the presence of blood
or urine ketone bodies, with blood bicarbonate
level <15 mmol/L. Signs of puberty were evaluated
at physical examination. The onset of puberty was
defined as breast development more than Tanner
stage II in girls and testicular size > 4 mL in boys.21
After the diagnosis was made, blood was
drawn for the detection of β-cell autoantibodies.
The serum samples were obtained and stored at
−80°C until assayed.
All of the patients had a 6-minute glucagon
test to assess their β-cell function at diagnosis.
After the fasting serum C-peptide sample was ob-
tained, 30 μg/kg glucagon (maximum 1 mg) was
given intravenously, and the second serum sample
was obtained 6 minutes later, to determine the
post-glucagon C-peptide level.22
GAD65 autoantibodies (GADAs), IA-2 auto-
antibodies (IA-2As) and insulin autoantibodies
(IAAs) were assayed using commercially available
radioimmunoassay kits (CIS Bio International,
Gif-Sur-Yvette Cedex, France). Human recombi-
nant full-length GAD65 protein and intracellular
fragment of the IA-2 protein, including amino acids
604–979 were labeled with I125. IAA detection
was based on the percentage binding of I125-
labelled insulin. Serum levels > 1 U/mL were con-
sidered positive for GADAs and IA-2As, whereas
serum level > 10% was considered positive for
IAAs. The intra-assay coefficients of variance of
these three assays were all < 5%, and inter-assay
coefficients of variance were all < 14%. These as-
says had disease sensitivities of 86%, 73% and
37% and specificities of 95%, 99% and 96% for
GADAs, IA-2As and IAAs, respectively, in the
Diabetes Autoantibody Standardization Program
workshop.23
Serum C-peptide levels were measured by 
radioimmunoassay (Daiichi Radioisotope Labo-
ratories, Tokyo, Japan).
Statistical analysis
The mean value and variance of the factors were
compared between the subgroups. The χ2 test was
used for categorical variables and the Mann–
Whitney U test or Kruskal–Wallis test was used
for numerical data. The correlations among the
variables were analyzed by the Pearson method
or logistic regression for categorical variables.
Multiple linear regression was used to analyze the
parameters associated with the dependent vari-
able of residual β-residual cell function at onset,
which was shown as post-glucagon C-peptide level.
Parameters such as age at onset, sex, glycated 
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hemoglobin, and presence of ketoacidosis, GADA,
IA-2A or IAA were independent variables of 
the analysis. A p value of < 0.05 was considered
statistically significant.
Results
The clinical data of patients with type 1 diabetes
(60 boys and 97 girls) are shown in Table 1. The
median age was 8.0 years (range: 1.2–18.0 years)
and 32% had entered puberty at diagnosis. Their
median body mass index (BMI) was 14.6 kg/m2
(range: 10.8–26.4 kg/m2) with a standard devia-
tion score of −1.0 (range: −3.1 to +3.2). Sixty-seven
percent had ketoacidosis as the initial presentation.
There were 114 patients (73%) positive for
GADAs, with a median value of 11.2 U/mL (range:
1.0–103.3 U/mL) (Table 1). One hundred and
twenty patients (76%) were positive for IA-2As,
with a median value of 11.8 U/mL (range: 1.0–
65.0 U/mL), whereas IAAs were positive in 33
patients at diagnosis (21%), with a median value
of 12.6% (range: 10–53%). Ninety-two percent
had at least one β-cell autoantibody detected and
64% had more than two of the autoantibodies
(Figure).
There were no differences in sex or metabolic
parameters between patients with and those with-
out β-cell autoantibodies. No age difference was
detected between GADA-positive and -negative
patients. There was also no difference in age be-
tween IA-2A-positive and -negative patients.
However, the IAA-positive patients tended to be
younger than the IAA-negative patients (5.9 ± 3.9
Table 1. Clinical characteristics of patients with type 1 diabetes
Age (yr) 0–5 (n = 40) 5–10 (n = 66) 10–18 (n = 51) Total (n = 157) p
Sex (male:female) 18:22 23:43 19:32 60:97 0.574¶
HbA1c* 12.1 12.3 13.7 12.5 < 0.001¦
(7.8–16.8) (6.2–17.3) (6.1–18.5) (6.1–18.5)
Ketoacidosis†‡ 35 (90) 42 (65) 26 (52) 103 (67) 0.001¶
C-peptide (nmol/L)*
Fasting 0.14 0.17 0.24 0.19 0.003¦
(0.1–0.49) (0.1–1.31) (0.1–1.19) (0.1–1.31)
Post-glucagon 0.17 0.32 0.39 0.30 < 0.001¦
(0.1–0.92) (0.1–1.98) (0.1–2.09) (0.1–2.09)
GADA positivity‡ 31 (78) 45 (68) 38 (75) 114 (73) 0.544¶
IA-2A positivity‡ 30 (75) 50 (76) 40 (78) 120 (76) 0.917¶
IAA positivity‡ 18 (45) 8 (12) 7 (14) 33 (21) < 0.001¶
Multiple antibodies‡§ 29 (72) 39 (59) 32 (63) 100 (64) 0.377¶
No detectable antibodies‡ 1 (3) 8 (12) 4 (8) 13 (8) 0.219¶
*Data presented as mean (range); †one missing data in each age group; ‡data presented as n (%); §more than two b-cell autoantibod-
ies were detected; ¦Kruskal–Wallis test; ¶Pearson’s c2 test. HbA1c = hemoglobin A1c; GADA = glutamic acid decarboxylase autoanti-
body; IA-2A = insulinoma antigen-2 autoantibody; IAA = insulin autoantibody.
GADA
19 (12%)
67 (43%)
IAA
0 (0%)
13 (8%)
23 (15%)
5 (3%)
1A–2A
25 (16%)
5 (3%)
Figure. The frequency of β-cell autoantibodies in Taiwanese
children with newly diagnosed type 1 diabetes. The figures
denote the numbers of patients positive for autoantibodies
and those in parentheses denote the percentage of these
patients.
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vs. 8.7 ± 3.7 years, p < 0.001). Forty-five percent of
patients who were < 5 years old had IAAs,
whereas IAAs were only detected in 13% of pa-
tients > 5 years old. The IAA titers in patients
aged < 5 years were also significantly higher than
those in older subjects (19.9% vs. 11.5%).
With regard to metabolic status, the presence
of ketoacidosis at onset was correlated negatively
with age of onset (r = –0.314, p < 0.001) and gly-
cated hemoglobin level was correlated positively
with age (r = 0.311, p < 0.001), as shown in Table 1.
After multiple regression analysis, residual β-cell
function was correlated positively with age of
onset (β = 0.458, p < 0.001) and presence of IAA
(β = 0.219, p = 0.003). It was correlated negatively
with the level of glycated hemoglobin (β= –0.385,
p < 0.001) and presence of GADA (β = –0.255,
p < 0.001), as shown in Table 2.
Discussion
Based on the low prevalence of β-cell autoanti-
bodies in Chinese patients with type 1 diabetes, it
has been proposed that immune-mediated mech-
anisms are not as important as in Caucasians.15–19
However, our study showed that 92% of Taiwanese
children with type 1 diabetes had at least one of
the β-cell autoantibodies detected and their
prevalence was similar to that of other popula-
tions.8–10,13,14 Varied inclusion criteria, such as
patient age and disease duration, might explain
partly the difference. Our study demonstrates that
autoimmunity still plays an important role in the
pathophysiology of type 1 diabetes in Taiwanese
children.
In our study population, 73% had GADAs
and 76% had IA-2As. The age of onset had no 
effect on the positive rate of GADAs and IA-2As.
However, the frequency of IAA positivity was 
significantly higher in patients with an onset age
< 5 years than that in older patients, as previ-
ously reported.24–27 Therefore, IAA had greater
diagnostic value in young children with type 1
diabetes than in older children.
The metabolic state at diagnosis was influenced
by the age of onset. Younger patients were more
prone to ketoacidosis as an initial presentation
than were older patients. The residual β-cell
function was correlated well with age of onset,
which indicated that younger patients had less
insulin reserve, which is consistent with other
studies.24,28 However, even after the exclusion of
the confounding effects of age and the presence of
other autoantibodies, the residual β-cell function
remained correlated positively with the presence
Table 2. Multiple linear regression for residual β-cell function
Post-glucagon C-peptide level (nmol/L)
Model 1: include all 
Model 2: include potential 
variables significantly associated Parameters
potential variables
with Pearson’s correlations
β ± SE p β ± SE p
Intercept 1.069 ± 0.170 < 0.001 0.992 ± 0.158 < 0.001
Age (yr) 0.440 ± 0.008 < 0.001 0.458 ± 0.007 < 0.001
Sex (male) −0.003 ± 0.057 0.965
HbA1c (%) −0.371 ± 0.012 < 0.001 −0.385 ± 0.012 < 0.001
GADA positivity −0.249 ± 0.063 0.001 −0.255 ± 0.062 < 0.001
IA-2A positivity −0.092 ± 0.064 0.193
IAA positivity 0.222 ± 0.072 0.003 0.219 ± 0.070 0.003
Ketoacidosis −0.061 ± 0.061 0.405
Adjusted R2 0.287 0.293
b = standardized coefficient; SE = standard error; HbA1c = hemoglobin A1c; GADA = glutamic acid decarboxylase autoantibody; 
IA-2 = insulinoma antigen-2 autoantibody; IAA = insulin autoantibody.
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of IAAs. This indicated that patients with IAAs 
at onset had more insulin reserve than those
without IAAs.
In cohort studies in Finland and Norway, IAA
has emerged as the first detectable β-cell auto-
antibody in high-risk pre-diabetic children.29,30
However, the studies also have shown that IAA
disappears more rapidly than the other autoanti-
bodies.29 Therefore, the fact that patients positive
for IAAs had more insulin reserve at disease onset
suggested that their pre-clinical period was shorter
than those without IAAs.
In addition to the factors of age and IAA, the
presence of GADA was another independent fac-
tor that was correlated negatively with residual 
β-cell function, which is consistent with other
studies.31,32 On the other hand, Decochez et al
have reported that the presence or absence of β-cell
autoantibodies does not affect β-cell function at
disease onset, but those with these autoantibod-
ies have a more rapid destruction of β-cell func-
tion.33 This is confirmed by our results.
In conclusion, our study demonstrates that
most type 1 diabetes in Taiwanese children is 
related to the immune-mediated destruction of
pancreatic islet cells. Among the detectable β-cell
autoantibodies, IAA is more common in younger
children, aged < 5 years, with type 1 diabetes.
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